NEW YORK, NY — August 5, 2026 — Leads & Copy — BeOne Medicines Ltd., a global oncology company, announced its financial results and corporate updates for the second quarter of 2026, reporting significant increases in revenue, income from operations, and net income compared to the prior year. Total revenue for the quarter reached $1.7 billion, a 30% increase over the second quarter of 2025. Net product revenues grew 29% to $1.68 billion, driven by strong performance in key products such as BRUKINSA and TEVIMBRA.
John V. Oyler, Co-Founder, Chairman, and CEO of BeOne, highlighted the company’s continued growth as a global oncology leader. He attributed the strong quarterly results to the momentum of its hematology franchise, led by BRUKINSA, and a robust pipeline. Oyler emphasized BeOne’s integrated capabilities spanning drug discovery, clinical development, manufacturing, and commercialization, positioning the company for future global expansion.
For the second quarter of 2026, GAAP income from operations was $325 million, a 270% increase from $87.9 million in the same period last year. GAAP net income rose 151% to $237 million, compared to $94.3 million in the second quarter of 2025. Earnings per American Depositary Share (ADS) also saw substantial growth, with GAAP diluted EPS at $2.05, up from $0.84 in the prior year.
Free Cash Flow for the second quarter of 2026 was $435 million, nearly doubling the $219.8 million reported in the second quarter of 2025, marking a 98% increase. This significant increase in free cash flow underscores the company’s strong operational performance and financial health.
Product revenues were bolstered by BRUKINSA, which generated global sales of $1.2 billion in the second quarter, a 31% increase year-over-year. U.S. sales of BRUKINSA contributed $893 million, also up 31%. TEVIMBRA achieved global sales of $229 million, an 18% increase, while Amgen in-licensed products generated $157 million, a 25% increase. The gross margin percentage for global product sales improved to 90% from 87% in the prior year, driven by a higher sales mix of BRUKINSA and productivity enhancements.
Operating expenses, both GAAP and non-GAAP, saw increases due to continued investment in research and development and commercial growth. Research and development expenses increased 17% on a GAAP basis to $612.3 million, while selling, general, and administrative expenses rose 10% to $593.2 million. On an adjusted basis, R&D increased 20% to $534 million, and SG&A increased 13% to $500.7 million.
BeOne also updated its full-year 2026 financial guidance, raising its total revenue forecast to $6.6 billion – $6.8 billion, an increase from the previous guidance of $6.3 billion – $6.5 billion. The company expects GAAP operating income to range from $1.0 billion to $1.1 billion, and non-GAAP operating income between $1.7 billion and $1.8 billion.
Significant business highlights for the second quarter included positive topline results from the Phase 3 MANGROVE study for BRUKINSA and U.S. accelerated approval for BEQALZI. TEVIMBRA received Japan regulatory approval for first-line gastric cancer. The company also announced a $300 million expansion of its manufacturing and R&D center in Hopewell, New Jersey, and appointed three new members to its Board of Directors: Felix J. Baker, Ph.D.; Elizabeth F. Mooney; and Charles L. Sawyers, M.D.
For more detailed financial information, BeOne’s Second Quarter 2026 Financial Statements are available in its Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission. The company will host its earnings conference call on August 5, 2026, at 8:00 a.m. ET.
Source: BeOne Medicines Ltd.
